Royalty Pharma headed into its Q1 2026 print with options traders already positioned for upside — and the results gave them reason to hold that view.
The earnings story is split down the middle. Adjusted EPS came in at $1.30, beating the $1.21 consensus by a meaningful 7%. Revenue, however, landed at $631 million against a $1.235 billion estimate — a sharp miss that reflects the timing quirks of royalty receipt recognition rather than underlying deal flow deterioration. Management raised full-year 2026 guidance, signalling confidence in the royalty pipeline despite the headline revenue shortfall. The stock is up 1.8% on the week to $50.44, a modest but positive reaction, and has added nearly 4% over the past month.
Options market positioning had already leaned bullish well before the print. The put/call ratio ended at 0.23 — more than one standard deviation below its 20-day average of 0.35 — making it one of the most call-heavy readings of the past year. The 52-week PCR range runs from 0.09 to 1.44, and the current reading sits close to the low end, pointing to concentrated demand for upside exposure rather than downside protection. That bullish tilt preceded the earnings beat, not the other way around. Short positioning adds little drama to the setup: at 2.8% of free float, shorts are a minor presence, and the 10% rise over the past month has been gradual rather than aggressive. Cost to borrow is negligible at 0.47%, and borrow availability is loose — no squeeze dynamics are visible in the lending market.
The Street is broadly constructive and has been nudging targets higher. UBS raised its target to $57 on April 21 while maintaining Buy, and Morgan Stanley lifted to $63 from $61 on April 10 — both moves coming ahead of today's results and signalling pre-print conviction. The mean price target sits at $52.75, a modest 4% premium to the current close, suggesting the market has largely repriced toward the bullish scenario already. The ORTEX short score of 34.5 is unremarkable — around the 65th percentile of its own history but not a flashing signal. EPS momentum scores are positive at the 68th percentile over 30 days, and the 12-month forward EPS growth factor ranks in the 100th percentile, a standout number for a company whose royalty stream is tied to late-stage blockbusters like semaglutide (Novo Nordisk) and cysplatin derivatives. P/E has drifted up to 9.6x and EV/EBITDA sits at 10.2x — neither demanding nor cheap for a royalty compounder.
One ownership detail worth noting: founder and CEO Pablo Legorreta added 157,828 shares in early April, nudging his stake to roughly 1.06% of the company. That contrasts with CFO Terrance Coyne, who sold approximately $3.4 million of stock across April 28 transactions — a continuation of a systematic selling pattern visible back to March. The CFO trades carry low significance scores and resemble a pre-scheduled disposal programme rather than directional positioning, but the divergence between founder buying and executive selling is worth tracking as the full-year guidance picture develops.
Close peer BMY fell 2.2% on the week, while MRK was roughly flat. TEVA stood out, gaining 13.4% over the same period on separate catalyst news. RPRX's 1.8% weekly advance puts it comfortably in the middle of its peer group — steady rather than reactive. What to watch now is whether the revenue miss triggers any re-evaluation from analysts who have been steadily raising targets, and how management characterises the timing of deferred royalty receipts on the Q1 call transcript.
See the live data behind this article on ORTEX.
Open RPRX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
